167 related articles for article (PubMed ID: 34351305)
1. Dual inhibition of FGFR4 and BCL-xL inhibits multi-resistant ovarian cancer with BCL2L1 gain.
Guo T; Gu C; Li B; Xu C
Aging (Albany NY); 2021 Aug; 13(15):19750-19759. PubMed ID: 34351305
[TBL] [Abstract][Full Text] [Related]
2. Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer.
Stover EH; Baco MB; Cohen O; Li YY; Christie EL; Bagul M; Goodale A; Lee Y; Pantel S; Rees MG; Wei G; Presser AG; Gelbard MK; Zhang W; Zervantonakis IK; Bhola PD; Ryan J; Guerriero JL; Montero J; Liang FJ; Cherniack AD; Piccioni F; Matulonis UA; Bowtell DDL; Sarosiek KA; Letai A; Garraway LA; Johannessen CM; Meyerson M
Mol Cancer Res; 2019 Nov; 17(11):2281-2293. PubMed ID: 31462500
[TBL] [Abstract][Full Text] [Related]
3. Silencing of FGFR4 could influence the biological features of gastric cancer cells and its therapeutic value in gastric cancer.
Ye Y; Jiang D; Li J; Wang M; Han C; Zhang X; Zhao C; Wen J; Kan Q
Tumour Biol; 2016 Mar; 37(3):3185-95. PubMed ID: 26432329
[TBL] [Abstract][Full Text] [Related]
4. BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer.
Ramesh P; Di Franco S; Atencia Taboada L; Zhang L; Nicotra A; Stassi G; Medema JP
Cell Rep; 2022 Feb; 38(7):110374. PubMed ID: 35172148
[TBL] [Abstract][Full Text] [Related]
5. Gain of 20q11.21 in human embryonic stem cells improves cell survival by increased expression of Bcl-xL.
Nguyen HT; Geens M; Mertzanidou A; Jacobs K; Heirman C; Breckpot K; Spits C
Mol Hum Reprod; 2014 Feb; 20(2):168-77. PubMed ID: 24217388
[TBL] [Abstract][Full Text] [Related]
6. Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation.
Ni F; Yan CY; Zhou S; Hui PY; Du YH; Zheng L; Yu J; Hu XJ; Zhang ZG
Cancer Chemother Pharmacol; 2018 Oct; 82(4):593-605. PubMed ID: 30032449
[TBL] [Abstract][Full Text] [Related]
7. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
8. Anti-apoptotic protein BCL-XL as a therapeutic vulnerability in gastric cancer.
Wei Y; Zhang L; Wang C; Li Z; Luo M; Xie G; Yang X; Li M; Ren S; Zhao D; Gao R; Gong JN
Animal Model Exp Med; 2023 Jun; 6(3):245-254. PubMed ID: 37271936
[TBL] [Abstract][Full Text] [Related]
9. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.
Crose LE; Etheridge KT; Chen C; Belyea B; Talbot LJ; Bentley RC; Linardic CM
Clin Cancer Res; 2012 Jul; 18(14):3780-90. PubMed ID: 22648271
[TBL] [Abstract][Full Text] [Related]
10. Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer.
Zhang H; Xue J; Hessler P; Tahir SK; Chen J; Jin S; Souers AJ; Leverson JD; Lam LT
Mol Cancer; 2015 Jul; 14():126. PubMed ID: 26134786
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition.
Weeden CE; Ah-Cann C; Holik AZ; Pasquet J; Garnier JM; Merino D; Lessene G; Asselin-Labat ML
Oncogene; 2018 Aug; 37(32):4475-4488. PubMed ID: 29743589
[TBL] [Abstract][Full Text] [Related]
12. Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.
Williams MM; Lee L; Hicks DJ; Joly MM; Elion D; Rahman B; McKernan C; Sanchez V; Balko JM; Stricker T; Estrada MV; Cook RS
Mol Cancer Res; 2017 Mar; 15(3):259-268. PubMed ID: 28039357
[TBL] [Abstract][Full Text] [Related]
13. ATF3 Repression of BCL-X
Chüeh AC; Tse JWT; Dickinson M; Ioannidis P; Jenkins L; Togel L; Tan B; Luk I; Davalos-Salas M; Nightingale R; Thompson MR; Williams BRG; Lessene G; Lee EF; Fairlie WD; Dhillon AS; Mariadason JM
Clin Cancer Res; 2017 Sep; 23(18):5573-5584. PubMed ID: 28611196
[No Abstract] [Full Text] [Related]
14. Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer.
Mu P; Nagahara S; Makita N; Tarumi Y; Kadomatsu K; Takei Y
Int J Cancer; 2009 Dec; 125(12):2978-90. PubMed ID: 19422046
[TBL] [Abstract][Full Text] [Related]
15. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
[TBL] [Abstract][Full Text] [Related]
16. Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis.
Brotin E; Meryet-Figuière M; Simonin K; Duval RE; Villedieu M; Leroy-Dudal J; Saison-Behmoaras E; Gauduchon P; Denoyelle C; Poulain L
Int J Cancer; 2010 Feb; 126(4):885-95. PubMed ID: 19634140
[TBL] [Abstract][Full Text] [Related]
17. Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation.
Roidl A; Berger HJ; Kumar S; Bange J; Knyazev P; Ullrich A
Clin Cancer Res; 2009 Mar; 15(6):2058-66. PubMed ID: 19240166
[TBL] [Abstract][Full Text] [Related]
18. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
19. Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition.
Blessing AM; Santiago-O'Farrill JM; Mao W; Pang L; Ning J; Pak D; Bollu LR; Rask P; Iles L; Yang H; Tran S; Elmir E; Bartholomeusz G; Langley R; Lu Z; Bast RC
Cancer; 2020 Aug; 126(15):3579-3592. PubMed ID: 32484926
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
